Avastin For Lung Cancer Will Be Free To Patients Who Beat The Average

Under a Genentech program that caps expenditures for Avastin, the oncologic will be free of charge to patients who continue using the therapy beyond the median duration of treatment for lung cancer

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet